Ferrer has sold its food division, Ferrer Alimentación, to IMCD as part of a strategic realignment focused on rare disease treatments.
Target Information
The Catalan pharmaceutical company Ferrer has recently concluded an agreement with the Dutch group IMCD for the sale of its food division, Ferrer Alimentación. The sale price remains undisclosed, but the subsidiary employs 37 staff and generated €112 million in revenue in 2024. Ferrer Alimentación specializes in providing ingredients for food and beverage production, including starches, sweeteners, and fermentations.
This divestiture is a strategic move as Ferrer focuses on reshaping its portfolio towards developing treatments for rare diseases. The sale aligns with Ferrer’s clear strategy of prioritizing investment in research and development (R&D), highlighted by its recent acquisition of the rights to the drug pridopidine for neurodegenerative diseases.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Spain
The Spanish market has witnessed a significant series of corporate transactions in recent months, reflecting the current trends in mergers and acquisitions (M&A). These trends include sector specialization, att
Similar Deals
IMCD
invested in
Ferrer Alimentación
in 2024
in a Other deal
Disclosed details
Transaction Size: $107M
Revenue: $119M
EBITDA: $15M